Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?
Is EWTX a good stock to buy? We came across a bullish thesis on Edgewise Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on EWTX.
Edgewise Therapeutics Inc. (EWTX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 15,518,492 | $630,516,330 | 11.68% | |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 10,215,455 | $415,053,937 | +39% | 7.77% |
| 3. | RA Capital Management Peter Kolchinsky | 8,392,730 | $340,996,620 | -20% | 2.96% |
| 4. | Driehaus Capital Richard Driehaus | 4,728,623 | $192,123,952 | +6% | 1.11% |
| 5. | Perceptive Advisors Joseph Edelman | 4,373,974 | $177,714,564 | -2% | 2.67% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.64 | 10,700 | $199,403.06 | 23,702 | 2025-11-11 | Filing | |
| $20.13 | 124,193 | $2,500,005.09 | 443,792 | 2025-04-03 | Filing | |
| $20.13 | 372,578 | $7,499,995.14 | 14,809,075 | 2025-04-03 | Filing | |
| $20.13 | 124,193 | $2,500,005.09 | 443,792 | 2025-04-03 | Filing | |
| $20.13 | 372,578 | $7,499,995.14 | 14,809,075 | 2025-04-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.41 | 2,919 | $126,703.57 | 8,625 | 2026-08-13 | Filing | |
| $44.52 | 800 | $35,614.00 | 11,544 | 2026-08-12 | Filing | |
| $44.43 | 104 | $4,620.23 | 12,344 | 2026-08-12 | Filing | |
| $43.71 | 2,779 | $121,462.59 | 12,448 | 2026-08-12 | Filing | |
| $43.78 | 2,839 | $124,302.78 | 15,227 | 2026-08-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,606,336 | $268,415,431 | 0% | |
| 2. | 6,075,331 | $246,945,299 | 0.1% | |
| 3. | 5,489,135 | $223,023,556 | 0.01% | |
| 4. | 5,350,000 | $217,370,500 | 12.62% | |
| 5. | 3,860,670 | $156,859,022 | 0% |
News See All
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
TheFly reported on June 17 that RBC Capital increased its price target for EWTX to $59 from $48 while maintaining an Outperform rating on the shares.
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
The U.S. healthcare sector has significantly lagged the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline
TheFly reported on March 17 that JPMorgan increased its price target for EWTX from $34 to $45 while keeping an Overweight rating on the stock.
13 Best Stocks to Invest In on Robinhood for Beginners
MacroMicro reports that as of March 18, 2026, the S&P 500's forward 12-month P/E was 21.35, which was far higher than its 10-year historical average of 18.9 but slightly lower than the 22.0x reported ...
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026
On the other hand, Edgewise Therapeutics, Inc.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported its Q3 2025 results on November 6, 2025. The quarter marked continued advancement of its muscular dystrophy and cardiac programs.
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small cap stocks with the highest upside. H.C.
Hedge Fund Resource Center